BridgeBio to present Phase 3 PROPEL 3 trial results for oral infigratinib in children with achondroplasia at ICCBH 2026

BridgeBio Pharma

BBIO

0.00

BridgeBio scheduled primary Phase 3 PROPEL 3 results on oral infigratinib in children with achondroplasia for ICCBH 2026.
Additional data were described as positive, supporting the program’s clinical and commercial outlook.
The late-breaking oral presentation is set for June 28, 2026, in Montreal.
Separate meeting presentations will cover quality-of-life findings from the observational PROPEL study.
A poster will also present baseline disease burden and quality-of-life findings from the CLARIFY monitoring study in autosomal dominant hypocalcemia.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606220730PRIMZONEFULLFEED9748546) on June 22, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.